Which has stronger earnings & valuation, RAPP or RLMD?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is RAPP or RLMD more profitable?

Rapport Therapeutics' return on equity of -29.02% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -29.02% -27.37% Relmada Therapeutics N/A -47.52% -43.97%

Does the media refer more to RAPP or RLMD?

In the previous week, Rapport Therapeutics had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Rapport Therapeutics and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat Rapport Therapeutics' score of 0.72 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor INVA or RLMD?

In the previous week, Innoviva and Innoviva both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of 1.79 beat Innoviva's score of 0.99 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PAHC or RLMD?

In the previous week, Relmada Therapeutics had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Phibro Animal Health. Relmada Therapeutics' average media sentiment score of 1.79 beat Phibro Animal Health's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RLMD or CRON?

In the previous week, Cronos Group had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for Cronos Group and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat Cronos Group's score of 0.86 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cronos Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, RLMD or AVLN?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A Avalyn Pharma N/A N/A N/A -$22.81 N/A

Is RLMD or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -47.52% -43.97% Avalyn Pharma N/A N/A N/A

Does the media prefer RLMD or AVLN?

In the previous week, Avalyn Pharma had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 5 mentions for Avalyn Pharma and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat Avalyn Pharma's score of 0.66 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avalyn Pharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relmada Therapeutics (RLMD) Competitors

$3.60 -0.06 (-1.64%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.66 +0.06 (+1.81%)

As of 10/2/2026 07:30 PM Eastern

Compare

RLMD vs. RAPP, INVA, PAHC, CRON, and AVLN

Should you buy Relmada Therapeutics stock or one of its competitors? Relmada Therapeutics's main competitors and comparable companies include Rapport Therapeutics (RAPP), Innoviva (INVA), Phibro Animal Health (PAHC), Cronos Group (CRON), and Avalyn Pharma (AVLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Relmada Therapeutics compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Rapport Therapeutics' return on equity of -29.02% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Rapport Therapeutics currently has a consensus target price of $66.25, suggesting a potential upside of 105.94%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 233.33%. Given Relmada Therapeutics' higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

45.2% of Relmada Therapeutics shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rapport Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Rapport Therapeutics had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Rapport Therapeutics and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat Rapport Therapeutics' score of 0.72 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Summary

Rapport Therapeutics and Relmada Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Innoviva?

Innoviva (NASDAQ:INVA) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Innoviva currently has a consensus price target of $39.25, indicating a potential upside of 91.46%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 233.33%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Innoviva has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Innoviva has a net margin of 81.19% compared to Relmada Therapeutics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Relmada Therapeutics	N/A	-47.52%	-43.97%

In the previous week, Innoviva and Innoviva both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of 1.79 beat Innoviva's score of 0.99 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.60	$271.17M	$4.10	5.00
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Summary

Innoviva beats Relmada Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

In the previous week, Relmada Therapeutics had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Phibro Animal Health. Relmada Therapeutics' average media sentiment score of 1.79 beat Phibro Animal Health's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Phibro Animal Health has a net margin of 6.57% compared to Relmada Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Phibro Animal Health currently has a consensus target price of $47.67, suggesting a potential upside of 28.00%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 233.33%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 48.5% of Phibro Animal Health shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phibro Animal Health has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	1.00	$99.72M	$2.44	15.26
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Summary

Phibro Animal Health beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Cronos Group?

Relmada Therapeutics (NASDAQ:RLMD) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 233.33%. Cronos Group has a consensus target price of $2.30, indicating a potential downside of 28.57%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relmada Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cronos Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 7.8% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cronos Group had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for Cronos Group and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat Cronos Group's score of 0.86 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cronos Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cronos Group has a net margin of 39.08% compared to Relmada Therapeutics' net margin of 0.00%. Cronos Group's return on equity of 4.85% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Cronos Group	39.08%	4.85%	4.62%

Cronos Group has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Cronos Group	$146.59M	8.10	-$9.45M	$0.20	16.10

Relmada Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Summary

Cronos Group beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Avalyn Pharma?

Relmada Therapeutics (NASDAQ:RLMD) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Avalyn Pharma had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 5 mentions for Avalyn Pharma and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.79 beat Avalyn Pharma's score of 0.66 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avalyn Pharma	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Avalyn Pharma	N/A	N/A	N/A

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 233.33%. Avalyn Pharma has a consensus price target of $60.00, suggesting a potential upside of 113.30%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Relmada Therapeutics and Avalyn Pharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$384.01M	$12.24B	$7.14B	$13.17B
Dividend Yield	N/A	2.64%	2.53%	16.78%
P/E Ratio	-4.00	799.70	275.68	26.04
Price / Sales	N/A	842.26	658.29	101.16
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	3.05	10.46	10.93	6.31
Net Income	-$57.38M	$2.84B	$3.51B	$362.16M
7 Day Performance	-6.01%	-1.57%	-2.00%	-1.66%
1 Month Performance	-17.62%	-5.67%	-6.15%	-4.50%
1 Year Performance	55.17%	-4.73%	7.44%	2.06%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.6114 of 5 stars	$3.60 -1.6%	$12.00 +233.3%	+35.3%	$384.01M	N/A	N/A	17	Positive News
RAPP Rapport Therapeutics	2.7481 of 5 stars	$32.37 -3.2%	$66.25 +104.7%	+12.7%	$1.55B	N/A	N/A	84	News Coverage Insider Trade
INVA Innoviva	3.2583 of 5 stars	$20.96 -1.3%	$34.80 +66.0%	+16.1%	$1.51B	$411.33M	5.10	159
PAHC Phibro Animal Health	4.4542 of 5 stars	$35.53 -0.5%	$47.67 +34.2%	-4.5%	$1.44B	$1.52B	14.58	2,605
CRON Cronos Group	1.3557 of 5 stars	$3.38 -1.0%	$2.30 -31.9%	+24.3%	$1.24B	$146.59M	16.88	610

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. RAPP, INVA, PAHC, CRON, and AVLN

How does Relmada Therapeutics compare to Rapport Therapeutics?

Summary

How does Relmada Therapeutics compare to Innoviva?

Summary

How does Relmada Therapeutics compare to Phibro Animal Health?

Summary

How does Relmada Therapeutics compare to Cronos Group?

Summary

How does Relmada Therapeutics compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. RAPP, INVA, PAHC, CRON, and AVLN

How does Relmada Therapeutics compare to Rapport Therapeutics?

Is RAPP or RLMD more profitable?

Do analysts prefer RAPP or RLMD?

Do institutionals & insiders hold more shares of RAPP or RLMD?

Which has more volatility and risk, RAPP or RLMD?

Does the media refer more to RAPP or RLMD?

Which has stronger earnings & valuation, RAPP or RLMD?

Summary

How does Relmada Therapeutics compare to Innoviva?

Do analysts recommend INVA or RLMD?

Which has more risk & volatility, INVA or RLMD?

Is INVA or RLMD more profitable?

Does the media favor INVA or RLMD?

Do insiders and institutionals believe in INVA or RLMD?

Which has higher earnings & valuation, INVA or RLMD?

Summary

How does Relmada Therapeutics compare to Phibro Animal Health?

Does the media favor PAHC or RLMD?

Is PAHC or RLMD more profitable?

Do analysts prefer PAHC or RLMD?

Do insiders and institutionals believe in PAHC or RLMD?

Which has more risk and volatility, PAHC or RLMD?

Which has stronger earnings & valuation, PAHC or RLMD?

Summary

How does Relmada Therapeutics compare to Cronos Group?

Do analysts rate RLMD or CRON?

Do insiders & institutionals believe in RLMD or CRON?

Does the media prefer RLMD or CRON?

Is RLMD or CRON more profitable?

Which has stronger valuation and earnings, RLMD or CRON?

Which has more risk & volatility, RLMD or CRON?

Summary

How does Relmada Therapeutics compare to Avalyn Pharma?

Which has higher valuation & earnings, RLMD or AVLN?

Do institutionals and insiders hold more shares of RLMD or AVLN?

Does the media prefer RLMD or AVLN?

Is RLMD or AVLN more profitable?

Do analysts prefer RLMD or AVLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools